Contact

“Antimicrobial resistance, I do believe, is the existential threat of this century.”
Admiral Brett P. Giroir, U.S. assistant secretary for health; Pew online, July 27, 2020

EVŌQ Bio is developing an antimicrobial platform with applications in pharmaceutical and medical/surgical applications.

Our antimicrobial therapeutic demonstrates efficacy against the worst of the world’s antibiotic resistant bacteria. Our uniquely elegant mechanism of action provides a biotechnology platform to create precise novel product outcomes for numerous applications and allows for multiple drug administration pathways.

Our key ingredient for an inhaled respiratory therapeutic—our primary focus—is now in its late-stage pre-clinical phase as we initiate our FDA path. Pre-clinical studies indicate our active pharmaceutical ingredient is non-toxic to lung epithelial cells and penetrates lung sputum to kill bacteria, rivaling tobramycin as a therapeutic. Furthermore, in vitro testing shows no development of compound resistance to our asset, demonstrating efficacy up to 21 days.

EVŌQ Bio’s API permeates biofilm, a protective environment for bacteria. Biofilm allows bacteria to thrive and become drug-resistant in a way that changes the physical nature of the biofilm, thus further protecting the bacteria.

             

In May 2019 we received a prestigious grant from the Cystic Fibrosis Foundation to better understand the effect of our therapeutic on the microbes that pose the greatest threats to CF patients. We partnered with Seattle Children’s Hospital and the University of Washington to conduct our studies. In October 2021 we received an additional grant from CFF to continue our research.

Our Team

The leadership team of EVŌQ Bio has over 50 years combined experience in healthcare and biotechnology research, in addition to years of leadership, management, and consulting experience. As a team, we are uniquely situated to break new ground in the advancement of next-generation biotechnology and pharmaceuticals.

Brian Bertha, CEO
Brian Bertha
President & CEO
Bretni Kennon
Dr. Bretni Kennon, Ph.D.
Chief Science Officer
William Niedermeyer
William Niedermeyer
Chief Technology Officer
David Nilson
David Nilson, MBA
VP Biotechnology
& Pharmaceuticals
Daniel Garner
Daniel Garner
Manager of Pharmaceutical Development

Memberships

Our Pipeline

Pulmonary infections

Indication Targets Drug/Therapeutic Candidate
    Discovery IND-Enabling Early Clinical
Cystic Fibrosis Burkholderia cenocepacia Pseudomonas aeruginosa Stenotrophomonas
Late-stage pre-clinical
Late-stage pre-clinical
EVQ-218
   
Bacterial Pneumonia Streptococcus pneumoniae Staphylococcus aureus Streptococcus pyogenes Klebsiella pneumoniae Haemophilus influenzae
Early-stage pre-clinical
Early-stage pre-clinical
EVQ-218
   
Pulmonary Fungal Infections Candida albicans Aspergillus
Early-stage pre-clinical
Early-stage pre-clinical
EVQ-218
   
Tuberculosis Mycobacterium tuberculosis
Early-stage pre-clinical
Early-stage pre-clinical
EVQ-218
   

Topical Infections

Indication Targets Drug/Therapeutic Candidate
    Discovery IND-Enabling Early Clinical
Cellulitis Group A β-hemolytic streptococcus Streptococcus pneumoniae
Late-stage pre-clinical
Late-stage pre-clinical
EVQ-221
   
Staph Skin Infections (e.g. MRSA) Methicillin-resistant Staphylococcus aureus
Early-stage pre-clinical
Early-stage pre-clinical
EVQ-221
   

Contact Us

Interested in learning more or partnering with us? Let’s connect!

1865 W 2100 S
Ste 150
Salt Lake City, UT 84119